uniQure N.V (UQ1) - Total Assets
Based on the latest financial reports, uniQure N.V (UQ1) holds total assets worth €778.71 Million EUR (≈ $910.39 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore uniQure N.V cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
uniQure N.V - Total Assets Trend (2016–2025)
This chart illustrates how uniQure N.V's total assets have evolved over time, based on quarterly financial data. See uniQure N.V net assets for net asset value and shareholders' equity analysis.
uniQure N.V - Asset Composition Analysis
Current Asset Composition (December 2025)
uniQure N.V's total assets of €778.71 Million consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.7% |
| Accounts Receivable | €5.86 Million | 0.7% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €72.79 Million | 8.8% |
| Goodwill | €25.36 Million | 3.1% |
Asset Composition Trend (2016–2025)
This chart illustrates how uniQure N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is uniQure N.V worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: uniQure N.V's current assets represent 79.5% of total assets in 2025, an increase from 75.7% in 2016.
- Cash Position: Cash and equivalents constituted 9.7% of total assets in 2025, down from 69.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 4.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 8.8% of total assets.
uniQure N.V Competitors by Total Assets
Key competitors of uniQure N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
uniQure N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.40 | 11.99 | 15.06 |
| Quick Ratio | 10.40 | 11.99 | 15.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €556.55 Million | €399.11 Million | €648.13 Million |
uniQure N.V - Advanced Valuation Insights
This section examines the relationship between uniQure N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.40 |
| Latest Market Cap to Assets Ratio | 1.77 |
| Asset Growth Rate (YoY) | 48.2% |
| Total Assets | €824.91 Million |
| Market Capitalization | $1.46 Billion USD |
Valuation Analysis
Above Book Valuation: The market values uniQure N.V's assets above their book value (1.77x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: uniQure N.V's assets grew by 48.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for uniQure N.V (2016–2025)
The table below shows the annual total assets of uniQure N.V from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €824.91 Million ≈ $964.40 Million |
+48.22% |
| 2024-12-31 | €556.54 Million ≈ $650.65 Million |
-33.08% |
| 2023-12-31 | €831.69 Million ≈ $972.33 Million |
+17.98% |
| 2022-12-31 | €704.96 Million ≈ $824.18 Million |
-12.88% |
| 2021-12-31 | €809.18 Million ≈ $946.02 Million |
+137.72% |
| 2020-12-31 | €340.39 Million ≈ $397.96 Million |
-24.13% |
| 2019-12-31 | €448.63 Million ≈ $524.50 Million |
+63.79% |
| 2018-12-31 | €273.91 Million ≈ $320.22 Million |
+30.65% |
| 2017-12-31 | €209.64 Million ≈ $245.10 Million |
+10.19% |
| 2016-12-31 | €190.26 Million ≈ $222.44 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more